CN111803792A - Generating device of space electric field - Google Patents
Generating device of space electric field Download PDFInfo
- Publication number
- CN111803792A CN111803792A CN202010285056.1A CN202010285056A CN111803792A CN 111803792 A CN111803792 A CN 111803792A CN 202010285056 A CN202010285056 A CN 202010285056A CN 111803792 A CN111803792 A CN 111803792A
- Authority
- CN
- China
- Prior art keywords
- electric field
- space
- electrode
- space electric
- generating
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000005684 electric field Effects 0.000 title claims abstract description 343
- 210000004881 tumor cell Anatomy 0.000 claims description 44
- 206010028980 Neoplasm Diseases 0.000 claims description 42
- 238000000034 method Methods 0.000 claims description 31
- 230000001105 regulatory effect Effects 0.000 claims description 15
- 231100000225 lethality Toxicity 0.000 claims description 12
- 230000002401 inhibitory effect Effects 0.000 claims description 11
- 230000001276 controlling effect Effects 0.000 claims description 9
- 210000004369 blood Anatomy 0.000 claims description 8
- 239000008280 blood Substances 0.000 claims description 8
- 238000012258 culturing Methods 0.000 claims description 8
- 230000008878 coupling Effects 0.000 claims description 6
- 238000010168 coupling process Methods 0.000 claims description 6
- 238000005859 coupling reaction Methods 0.000 claims description 6
- 239000000523 sample Substances 0.000 claims description 6
- 230000004565 tumor cell growth Effects 0.000 claims description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 6
- 230000000903 blocking effect Effects 0.000 claims description 5
- 230000012010 growth Effects 0.000 claims description 5
- 238000012360 testing method Methods 0.000 claims description 5
- 206010003210 Arteriosclerosis Diseases 0.000 claims description 4
- 208000007536 Thrombosis Diseases 0.000 claims description 4
- 208000011775 arteriosclerosis disease Diseases 0.000 claims description 4
- 210000000467 autonomic pathway Anatomy 0.000 claims description 4
- 210000004204 blood vessel Anatomy 0.000 claims description 4
- 210000004556 brain Anatomy 0.000 claims description 4
- 230000036039 immunity Effects 0.000 claims description 4
- 230000001976 improved effect Effects 0.000 claims description 4
- 210000001178 neural stem cell Anatomy 0.000 claims description 4
- 210000002569 neuron Anatomy 0.000 claims description 4
- 230000004936 stimulating effect Effects 0.000 claims description 4
- 239000003053 toxin Substances 0.000 claims description 4
- 231100000765 toxin Toxicity 0.000 claims description 4
- 108700012359 toxins Proteins 0.000 claims description 4
- 230000000694 effects Effects 0.000 abstract description 28
- 230000008901 benefit Effects 0.000 abstract description 2
- 238000004519 manufacturing process Methods 0.000 abstract description 2
- 210000004027 cell Anatomy 0.000 description 75
- 230000009471 action Effects 0.000 description 21
- 210000001519 tissue Anatomy 0.000 description 20
- 230000008859 change Effects 0.000 description 11
- 230000002147 killing effect Effects 0.000 description 11
- 201000011510 cancer Diseases 0.000 description 10
- 239000000243 solution Substances 0.000 description 10
- 210000000170 cell membrane Anatomy 0.000 description 9
- 201000001441 melanoma Diseases 0.000 description 9
- 238000002059 diagnostic imaging Methods 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 8
- 241000124008 Mammalia Species 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 6
- 241000288906 Primates Species 0.000 description 6
- 230000005764 inhibitory process Effects 0.000 description 6
- 239000011159 matrix material Substances 0.000 description 6
- 230000011278 mitosis Effects 0.000 description 6
- 238000004113 cell culture Methods 0.000 description 5
- 230000007246 mechanism Effects 0.000 description 5
- 230000004614 tumor growth Effects 0.000 description 5
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 4
- 229910002092 carbon dioxide Inorganic materials 0.000 description 4
- 238000004520 electroporation Methods 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 208000005017 glioblastoma Diseases 0.000 description 4
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 241000282693 Cercopithecidae Species 0.000 description 3
- 241000283953 Lagomorpha Species 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 241000283089 Perissodactyla Species 0.000 description 3
- 241000283984 Rodentia Species 0.000 description 3
- 241001493546 Suina Species 0.000 description 3
- 239000006285 cell suspension Substances 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 230000000394 mitotic effect Effects 0.000 description 3
- 230000035699 permeability Effects 0.000 description 3
- 238000007920 subcutaneous administration Methods 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 208000032612 Glial tumor Diseases 0.000 description 2
- 206010018338 Glioma Diseases 0.000 description 2
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 2
- 102000029749 Microtubule Human genes 0.000 description 2
- 108091022875 Microtubule Proteins 0.000 description 2
- 229930182555 Penicillin Natural products 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 239000001569 carbon dioxide Substances 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 238000005345 coagulation Methods 0.000 description 2
- 230000015271 coagulation Effects 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000008595 infiltration Effects 0.000 description 2
- 238000001764 infiltration Methods 0.000 description 2
- 210000004969 inflammatory cell Anatomy 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 230000002427 irreversible effect Effects 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 210000004688 microtubule Anatomy 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 229940049954 penicillin Drugs 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 230000020347 spindle assembly Effects 0.000 description 2
- 229960005322 streptomycin Drugs 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 230000000007 visual effect Effects 0.000 description 2
- 108091060290 Chromatid Proteins 0.000 description 1
- 108010077544 Chromatin Proteins 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 230000005526 G1 to G0 transition Effects 0.000 description 1
- 201000010915 Glioblastoma multiforme Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 108010061100 Nucleoproteins Proteins 0.000 description 1
- 102000011931 Nucleoproteins Human genes 0.000 description 1
- 108010019160 Pancreatin Proteins 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 206010053615 Thermal burn Diseases 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 102000004243 Tubulin Human genes 0.000 description 1
- 108090000704 Tubulin Proteins 0.000 description 1
- 230000036982 action potential Effects 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 201000007983 brain glioma Diseases 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 210000003855 cell nucleus Anatomy 0.000 description 1
- 210000004756 chromatid Anatomy 0.000 description 1
- 210000003483 chromatin Anatomy 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 238000011262 co‐therapy Methods 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000035617 depilation Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 230000005611 electricity Effects 0.000 description 1
- 238000003487 electrochemical reaction Methods 0.000 description 1
- 238000005868 electrolysis reaction Methods 0.000 description 1
- 238000005370 electroosmosis Methods 0.000 description 1
- 230000005686 electrostatic field Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 238000009093 first-line therapy Methods 0.000 description 1
- 210000003194 forelimb Anatomy 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 230000028161 membrane depolarization Effects 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 230000035773 mitosis phase Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 238000011580 nude mouse model Methods 0.000 description 1
- 229940055695 pancreatin Drugs 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000009094 second-line therapy Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
- A61N1/36—Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
- A61N1/36002—Cancer treatment, e.g. tumour
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
- A61N1/326—Applying electric currents by contact electrodes alternating or intermittent currents for promoting growth of cells, e.g. bone cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
- A61N1/36—Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
- C12M1/00—Apparatus for enzymology or microbiology
- C12M1/42—Apparatus for the treatment of microorganisms or enzymes with electrical or wave energy, e.g. magnetism, sonic waves
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
- C12M35/00—Means for application of stress for stimulating the growth of microorganisms or the generation of fermentation or metabolic products; Means for electroporation or cell fusion
- C12M35/02—Electrical or electromagnetic means, e.g. for electroporation or for cell fusion
-
- H—ELECTRICITY
- H01—ELECTRIC ELEMENTS
- H01T—SPARK GAPS; OVERVOLTAGE ARRESTERS USING SPARK GAPS; SPARKING PLUGS; CORONA DEVICES; GENERATING IONS TO BE INTRODUCED INTO NON-ENCLOSED GASES
- H01T19/00—Devices providing for corona discharge
- H01T19/04—Devices providing for corona discharge having pointed electrodes
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Radiology & Medical Imaging (AREA)
- Biotechnology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Physics & Mathematics (AREA)
- Cell Biology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Sustainable Development (AREA)
- Microbiology (AREA)
- Plasma & Fusion (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Electromagnetism (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Medicinal Chemistry (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
The invention provides a generating device of a space electric field, which at least comprises: a space electric field contact electrode; the space electric field outer electrode is used for forming a space electric field with the space electric field contact electrode; the device comprises more than 2 different electrodes, and the positions of the different electrodes are adjustable and are used for adjusting the coverage area of a space electric field. The generating device of the space electric field has the advantages of low production cost, stronger applicability, better treatment effect, higher safety performance and wider application.
Description
Technical Field
The invention relates to the field of medical treatment, in particular to a generating device of a space electric field.
Background
The electric field tumor treatment technology is a comprehensive subject of applying electricity to treat malignant tumors. The effect of electric fields on tumor cells has been around for a century since its introduction, and as the theory matures, electric fields have begun to be applied to the clinical treatment of tumors. At present, the following 3 electric field technologies are mainly studied at home and abroad: space electric Fields (TT-Fields), dc electric Fields, and dc pulsed electric Fields.
1. Overview of space electric Fields (TT-Fields)
Alternating current electric fields have been widely used in many fields such as disease diagnosis, scientific research and environmental protection. Less than 103z, which is used to stimulate the bioelectrical activity of nerves or muscles, can cause cells to generate action potentials; higher than 106The high frequency alternating electric field of Hz produces a thermal effect on some cells or tissues. Between 103Hz and 106The Hz medium-frequency alternating current electric field can not cause depolarization and large dielectric dissipation, and has the effect of interfering the mitosis of cells.
1.1 TT-Fields mechanism for inhibiting cancer cell division
Some charged molecules (such as protein, polypeptide and DNA) in the cell oscillate with the change of the alternating current electric field. In the shimming electric field, the action force makes the moving direction of the charged molecules parallel to the direction of the electric field. Dipoles are molecules separated by a cathode and an anode, whose directions coincide with the direction of the electric field. Almost all charged molecules move in the direction of strong field strength in a changing alternating electric field. In the cells at the end stage of mitosis, the cleavage furrow is divided into two daughter cells connected by a narrow cytoplasm, an uneven electric field is formed near the connection site, and polar molecules move towards the direction of strong field intensity, thereby influencing mitosis.
(1) Arrest of mitotic spindle formation
The role of the spindle in mitosis is to divide sister chromatids evenly into two daughter cells. In cells that do not divide, microtubule subunits will align in parallel depending on the direction of the electric field. During the mitotic phase of the cell, tubulin is subject to an electric field of suitable strength to cause polymerization inhibition, which hinders microtubule formation. Which in turn causes the cells to fragment.
(2) Disruption of mitotic groove
Blocking spindle formation occurs in all cells in mitosis. In cells in the late mitosis phase, the two daughter chromosomes will be pulled to the two poles of the cell. Just at the end of mitosis, the cleavage furrow eventually forms and two identical cells will form. At this narrow cell membrane junction, a non-uniform electrical field like a sand-leak will be generated. The position of the maximum field strength is the central position of the narrow part, and the field strength causes the charged particles to be acted by a unidirectional electric field force, so that the charged particles move towards the splitting channel. The TT-Fields also use the principle to disorder the intracellular structure and generate the cell destruction effect.
1.2 therapeutic characteristics of TT-Fields
TT-Fields is that an insulating electrode slice is put on the skin at the periphery of a malignant tumor growth part to provide an electric field, and an electric field device works for 18 hours on average every day to form two mutually perpendicular alternating current electric Fields with the strength of 1-2V/cm and the frequency of 200 kHz. Can cover almost all the possible diseased areas of the human body and has no influence on non-differentiated cells. It has been reported that TT-Fields treatment has not found any toxic side effects, except that the contact of the electrode patch in the treatment device with the skin may cause local dermatitis. In addition, it has been shown that TT-Fields have low toxicity, good patient response and high co-therapy level.
2 d.c. electric field
Direct current electric field therapy, i.e. electrochemical therapy, is to insert electrodes as a cathode and an anode into tumor tissues, and to continuously electrify the tumor tissues to generate electrochemical reactions such as electrolytic ionization, electrophoretic electroosmosis and the like, thereby achieving the purpose of destroying or influencing tumor cells. In recent years, although many scientists have studied the mechanism of electrochemical treatment of tumor, the mechanism is still not very clear, and the main principle of the electrochemical treatment is that after the electrochemical treatment, the pH value of the tissue around the electrode changes significantly, the pH value of the tumor cell and the surrounding tissue is changed forcibly, most of enzyme protein is inactivated and denatured in the environment with the pH less than or equal to 4 or the pH more than or equal to 10, the permeability of the cell membrane is changed, and the tumor has various pathological effects such as cell nucleus coagulation, cell membrane collapse, mitochondrial disappearance, necrosis of the cell due to the coagulation of the nucleoprotein and the like, and finally the cancer cell dies.
3. Pulsed electric field
The pulse electric field contains various frequencies from low to high, the action time is extremely short, the caused biological effect is greatly different from a direct current electric field or an electrostatic field, cells can quickly reach the maximum membrane voltage under the action of the external electric field, cell membranes become thin under the action of electric field stress, and the cell membranes are broken down to generate electroporation when reaching a certain critical point. When the intensity of the applied instantaneous pulse electric field is more than 1kV/cm, the permeability of molecules in the cells can be greatly improved; if the pulsed electric field strength continues to increase, irreversible electroporation of the cell membrane will occur. Pulsed electric fields can be divided into two broad categories, specifically as follows:
3.1 electric pulse chemotherapy
Electric Pulse Chemotherapy (EPCT) is a method of tumor treatment that combines the action of a pulsed electric field with a chemical drug. The low-intensity pulse electric field can cause reversible electroporation to cell membranes, the permeability of the cell membranes is increased, the exchange of internal and external molecules is increased, and the local administration is facilitated to play a role. The degree of cell membrane penetration depends on the strength and duration of the pulsed electric field, the size of the target cell, etc. At present, the EPCT has a definite treatment effect on superficial tumors such as skin or subcutaneous tumors, but has no relevant result on the treatment effect on deep tumors.
3.2 nanosecond pulsed electric field
Nanosecond pulsed electric fields (nsPEF) refer to steep pulsed electric fields with a pulse width on the order of nanoseconds, which can cause irreversible electroporation of tumor cell membranes. At present, the research on the tumor treatment by the steep pulse electric field at home and abroad has made great progress, and the nsPEF technology provides a high-efficiency tool without energy dependence for the treatment of malignant tumor. The anti-tumor mechanism is complex, and can cause apoptosis except directly destroying tumor cells, but the specific mechanism of nsPEF for inducing apoptosis of tumor cells is not completely clear.
Currently, only novo-kuler (Novocure) limited worldwide developed a NOVOTTF-100A medium frequency alternating electric field tumor treatment facility for clinical use, which was approved by the FDA in the united states in 2011 as a second line therapy after failure of first line therapy of recurrent glioblastoma multiforme. A patent (CN1976738B, entitled tumor treatment using electric fields of different frequencies) filed by norwalk coulter, ltd in china, which claims a device comprising an AC voltage source, insulated electrodes; the electric field frequency of the special claim belongs to middle and low frequency, and mainly takes low frequency (the low frequency is generally 30-300 KHZ according to the frequency division standard, and the intermediate frequency is generally 300-3000 KHZ).
Existing electric field treatment devices and techniques have their drawbacks. First, since different types of tumors have different sensitivities to field intensity, when an electric field of a fixed intensity is used to treat a tumor, cells, tissues, or organs in a normal region cause changes in electric field lines, so that it is difficult to determine the actual electric field intensity with which the tumor cells are in contact, and accurate electric field treatment cannot be performed, which may cause the electric field intensity to fail to achieve the therapeutic effect. Secondly, the frequency of the electric field is mainly low frequency, which can generate low frequency current, and the low frequency current can cause the ion concentration in the human body cells to change and generate electrolysis in the medium of the tissue to form harmful substances. Thirdly, if the insulating layer of the insulated electrode fails or breaks down, the body can be seriously damaged, so that the potential safety hazard exists in the clinical application of the insulated electrode. Fourth, wearing electrodes in direct contact with the skin for extended periods of time can lead to allergic reactions in the skin.
Disclosure of Invention
In view of the above-mentioned drawbacks of the prior art, it is an object of the present invention to provide a device for generating a spatial electric field.
To achieve the above and other related objects, the present invention provides a generating device of a space electric field, comprising at least:
a space electric field contact electrode;
the space electric field outer electrode is used for forming a space electric field with the space electric field contact electrode; the device comprises more than 2 different electrodes, and the positions of the different electrodes are adjustable and are used for adjusting the coverage area of a space electric field.
The second aspect of the present invention provides a method for generating a space electric field, comprising at least the following steps:
1) providing a space electric field contact electrode, and enabling the space electric field contact electrode to contact a living organism;
2) providing a space electric field outer electrode, wherein the space electric field outer electrode comprises more than 2 different electrodes, and the position of each different electrode is adjustable and is used for adjusting the coverage area of the space electric field;
3) and switching on the space electric field contact electrode and the space electric field outer electrode to generate a space electric field.
A third aspect of the present invention provides a method for using the aforementioned device for generating a space electric field, the method at least comprising the steps of:
1) connecting the space electric field contact electrodes of the object to be detected to enable the object to be detected and the space electric field contact electrodes to form an equipotential;
2) and adjusting the position of each different electrode to adjust the coverage area of the space electric field.
In a fourth aspect, the invention provides a method for selectively destroying or inhibiting the growth of tumor cells in a subject, which is to place the subject in the generating device of the space electric field.
The fifth aspect of the present invention provides a use of the aforementioned generating apparatus of a space electric field or the aforementioned generating method of a space electric field, including one or more of: (1) selectively destroying or inhibiting tumor cell growth in a test subject;
(2) selectively modulating or stimulating the division/growth rate of, for example, brain neural stem cells or neuronal cells;
(3) reducing blood fat; (4) improving arteriosclerosis; (5) preventing the thrombus from blocking the blood vessel; (6) removing toxins from the blood;
(7) modulating autonomic nerves; (8) the immunity of human body is improved by regulating/eliminating free radicals.
As described above, the device for generating a spatial electric field according to the present invention has the following advantageous effects:
(1) the applicability is stronger, and the treatment effect is better.
(2) The safety performance is higher.
(3) The production cost is low.
(4) Has wide application.
Drawings
FIG. 1 is a schematic structural diagram of a device for generating a space electric field according to the present invention.
FIG. 2 is a schematic diagram showing the arrangement of the different electrodes of the external electrode of the space electric field according to the present invention.
Fig. 3 shows the results of the diagnostic imaging before and after the electric field treatment of human melanoma cell B16F 10.
Fig. 4 shows the results of the diagnostic imaging before and after electric field treatment of human melanoma cell a 431.
FIG. 5 shows the results of diagnostic imaging of glioblastoma cell line SNB-19 before and after electric field treatment.
Fig. 6 shows the results of the diagnostic imaging before and after electric field treatment of human melanoma cell a 172.
Fig. 7 shows the effect of electric field therapy (n-6, 60 KV/cm).
Detailed Description
The following description of the embodiments of the present invention is provided for illustrative purposes, and other advantages and effects of the present invention will become apparent to those skilled in the art from the present disclosure.
Please refer to fig. 1 to 7. It should be understood that the structures, ratios, sizes, and the like shown in the drawings and described in the specification are only used for matching with the disclosure of the specification, so as to be understood and read by those skilled in the art, and are not used to limit the conditions under which the present invention can be implemented, so that the present invention has no technical significance, and any structural modification, ratio relationship change, or size adjustment should still fall within the scope of the present invention without affecting the efficacy and the achievable purpose of the present invention. In addition, the terms "upper", "lower", "left", "right", "middle" and "one" used in the present specification are for clarity of description, and are not intended to limit the scope of the present invention, and the relative relationship between the terms and the terms is not to be construed as a scope of the present invention.
Unless otherwise indicated, the experimental methods, detection methods, and preparation methods disclosed herein all employ techniques conventional in the art of molecular biology, biochemistry, chromatin structure and analysis, analytical chemistry, cell culture, recombinant DNA technology, and related arts.
As shown in fig. 1, the present invention provides a generating device of a space electric field, the generating device at least comprises:
a space electric field contact electrode;
the space electric field outer electrode is used for forming a space electric field with the space electric field contact electrode; the device comprises more than 2 different electrodes, and the positions of the different electrodes are adjustable and are used for adjusting the coverage area of a space electric field.
Furthermore, the space electric field contact electrode is used for being connected with an object to be detected, so that the object to be detected and the space electric field contact electrode form an equipotential.
The object to be detected is an animal living body. Further, it is a mammal. The mammal is preferably a rodent, artiodactyla, perissodactyla, lagomorpha, primate, or the like. The primate is preferably a monkey, ape or human.
In one embodiment, the space electric field contact electrode is grounded.
Further, the outer electrode of the space electric field is not contacted with the object to be detected.
In one embodiment, the generating means further comprises:
the power supply is used for supplying electric energy to the generating device;
and the regulating and controlling unit is used for regulating and controlling the performance of the space electric field, and comprises one or more of electric field intensity, electric field direction, electric field pulse frequency and electric field lattice range.
In one embodiment, the regulation unit can adjust the frequency, waveform and amplitude of the power supply, so that the frequency, waveform and voltage of the output high voltage are changed. The energy intensity, frequency and vibration acting on the cells are changed. The difference between the normal tissue and the controlled tissue is distinguished.
In one embodiment, the regulating unit may adjust the frequency, the magnitude, and the waveform of the voltage to generate the target electric field strength. The effect on different types of tissues and cells is realized by adjusting the target electric field intensity.
The regulating unit can be used for selectively supplying power to different electrodes so as to regulate the action area of the space electric field and the electric field intensity. By detecting the change of the electric field coupling current, the action range of the electric field and the action depth and position of the electric field can be tracked.
The space electric field contact electrode does not influence the position of the different electrode or the selection of the electrifying condition.
In one embodiment, the position of the counter electrode and/or the performance of the spatial electric field is confirmed from other diagnostic data; and/or the position, the number and/or the space electric field performance of the different electrodes are automatically tracked and adjusted after being diagnosed according to the electric field coupling current.
In one embodiment, the method for determining the electric field strength of the space electric field is:
1) culturing tumor cells under electric fields with different electric field intensities, and counting the lethality rate of the tumor cells, wherein the tumor cells are the same as the tumor types suffered by the object to be detected;
2) and selecting the electric field intensity range of the group with the highest tumor cell lethality as the electric field intensity range of the space electric field.
In one embodiment, the space electric field contact electrode and the object to be detected are contacted through water as conductive contact.
In one embodiment, the power supply is a high voltage output power supply.
In one embodiment, the voltage of the power supply is adjustable between 0.001kv and 120kv, the current output is adjustable between 0.001ma and 10000ma, and the working distance of the electric field is adjustable between 0.1cm and 100 cm.
In one embodiment, the counter electrode is a point-like probe.
In one embodiment, the different electrodes may be arranged to form matrix different electrodes to form a spatial lattice electric field, and the spatial lattice electric field is precisely controlled to adapt to the action range according to the action range of the drug or the medical imaging data related to the tumor.
In one embodiment, the arrangement of the different electrodes may be selected from a dot matrix arrangement, and may be 2nWherein n is a non-0 natural number. Such as a 64 lattice, a 4096 lattice, a 16777216 lattice, etc., as shown in fig. 2. The degree of lattice density depends on the accuracy of the electric field. The precise action electric field is utilized to improve the action efficiency on tumor cells and reduce the influence on normal tissues. But is limited by the volume of the output electric field power supply, the lattice is dense and the power supply is large. Wherein any one or more longitude lines from a \ b \ c to xx and any one or more latitude lines from 1\2\3 to nn activate one or more lattice heteropolars, the heteropolars and equipotential poles form an action electric field, and the coverage range of the electric field is determined by the activated lattice poles. This range may come from the coupled nature of the tumor cells in the electric field or other medical diagnostic imaging digital signals. Confirming the electric field range, the tumor cells can be accurately acted, and the influence on other tissues is reduced. Generally, 64 dot matrixes can only distinguish 64 electric field positions, 4096 dot matrixes can distinguish 4096 electric field positions, 16777216 dot matrixes can distinguish 16777216 electric field positions, the dot matrix effect is relatively accurate, and the image of surrounding normal tissues is small.
The invention also provides a method for generating the space electric field, which at least comprises the following steps:
1) providing a space electric field contact electrode, and enabling the space electric field contact electrode to contact a living organism;
2) providing a space electric field outer electrode, wherein the space electric field outer electrode comprises more than 2 different electrodes, and the position of each different electrode is adjustable and is used for adjusting the coverage area of the space electric field;
3) and switching on the space electric field contact electrode and the space electric field outer electrode to generate a space electric field.
The living organism refers to an animal living organism. Further, it is a mammal. The mammal is preferably a rodent, artiodactyla, perissodactyla, lagomorpha, primate, or the like. The primate is preferably a monkey, ape or human.
Further, the method also comprises adjusting and controlling the performance of the space electric field, wherein the performance comprises one or more of electric field intensity, electric field direction, electric field pulse frequency and electric field lattice range.
In one embodiment, the space electric field contact electrode is grounded.
In one embodiment, the counter electrode is a point-like probe.
In one embodiment, the arrangement of the different electrodes is selected from a lattice arrangement and is 2nLattice, where n is a non-0 natural number. Such as a 64 lattice, a 4096 lattice, a 16777216 lattice, etc., as shown in fig. 2. The degree of lattice density depends on the accuracy of the electric field.
In one embodiment, the space electric field contact electrode is in conductive contact with the living organism through water.
In one embodiment, the external electrode of the space electric field is not in contact with the living organism.
In one embodiment, the voltage of the power supply is adjustable between 0.001kv and 120kv, the current output is adjustable between 0.001ma and 10000ma, and the working distance of the electric field is adjustable between 0.1cm and 100 cm.
In one embodiment, the method for confirming the electric field strength of the space electric field comprises the following steps:
1) culturing tumor cells under electric fields with different electric field intensities, and counting the lethality rate of the tumor cells, wherein the tumor cells are the same as the tumor types suffered by the object to be detected;
2) and selecting the electric field intensity range of the group with the highest tumor cell lethality as the electric field intensity range of the space electric field.
The invention also provides a use method of the generating device of the space electric field, which is characterized by at least comprising the following steps:
1) connecting the space electric field contact electrodes of the object to be detected to enable the object to be detected and the space electric field contact electrodes to form an equipotential;
2) and adjusting the position of each different electrode to adjust the coverage area of the space electric field.
Further, the object to be detected is an animal living body. Further, it is a mammal. The mammal is preferably a rodent, artiodactyla, perissodactyla, lagomorpha, primate, or the like. The primate is preferably a monkey, ape or human.
In one embodiment, the space electric field contact electrode is grounded.
Further, the outer electrode of the space electric field is not contacted with the object to be detected.
In one embodiment, the generating means further comprises:
the power supply is used for supplying electric energy to the generating device;
and the regulating and controlling unit is used for regulating and controlling the performance of the space electric field, and comprises one or more of electric field intensity, electric field direction, electric field pulse frequency and electric field lattice range.
In one embodiment, the regulation unit can adjust the frequency, waveform and amplitude of the power supply, so that the frequency, waveform and voltage of the output high voltage are changed. The energy intensity, frequency and vibration acting on the cells are changed. The difference between the normal tissue and the controlled tissue is distinguished.
In one embodiment, the regulating unit may adjust the frequency, the magnitude, and the waveform of the voltage to generate the target electric field strength. The effect on different types of tissues and cells is realized by adjusting the target electric field intensity.
The regulating unit can be used for selectively supplying power to different electrodes so as to regulate the action area of the space electric field and the electric field intensity. By detecting the change of the electric field coupling current, the action range of the electric field and the action depth and position of the electric field can be tracked.
The space electric field contact electrode does not influence the position of the different electrode or the selection of the electrifying condition.
In one embodiment, the position of the counter electrode and/or the performance of the spatial electric field is confirmed from other diagnostic data; and/or the position, the number and/or the space electric field performance of the different electrodes are automatically tracked and adjusted after being diagnosed according to the electric field coupling current.
In one embodiment, the method for determining the electric field strength of the space electric field is:
1) culturing tumor cells under electric fields with different electric field intensities, and counting the lethality rate of the tumor cells, wherein the tumor cells are the same as the tumor types suffered by the object to be detected;
2) and selecting the electric field intensity range of the group with the highest tumor cell lethality as the electric field intensity range of the space electric field.
In one embodiment, the space electric field contact electrode and the object to be detected are contacted through water as conductive contact.
In one embodiment, the power supply is a high voltage output power supply.
In one embodiment, the voltage of the power supply is adjustable between 0.001kv and 120kv, and the current output is adjustable between 0.001ma and 10000 ma.
In one embodiment, the counter electrode is a point-like probe.
In one embodiment, the different electrodes may be arranged to form matrix different electrodes to form a spatial lattice electric field, and the spatial lattice electric field is precisely controlled to adapt to the action range according to the action range of the drug or the medical imaging data related to the tumor.
In one embodiment, the arrangement of the different electrodes may be selected from a dot matrix arrangement, and may be 2nWherein n is a non-0 natural number. Such as a 64 lattice, a 4096 lattice, a 16777216 lattice, etc., as shown in fig. 2. The degree of lattice density depends on the accuracy of the electric field. The precise action electric field is utilized to improve the action efficiency on tumor cells and reduce the influence on normal tissues. But is limited by the volume of the output electric field power supply, the lattice is dense and the power supply is large. Wherein any one or more longitude lines from a \ b \ c to xx and any one or more latitude lines from 1\2\3 to nn activate one or more lattice heteropolars, the heteropolars and equipotential poles form an action electric field, and the coverage range of the electric field is determined by the activated lattice poles. This range may come from the coupled nature of the tumor cells in the electric field or other medical diagnostic imaging digital signals. Confirming the electric field range, the tumor cells can be accurately acted, and the influence on other tissues is reduced. Generally, 64 dot matrixes can only distinguish 64 electric field positions, 4096 dot matrixes can distinguish 4096 electric field positions, 16777216 dot matrixes can distinguish 16777216 electric field positions, the dot matrix effect is relatively accurate, and the image of surrounding normal tissues is small.
The invention also provides a method for selectively destroying or inhibiting the growth of tumor cells in a to-be-detected object, which is to place the to-be-detected object in the generating device of the space electric field.
The invention also provides a generating device of the space electric field or a generating method of the space electric field, which comprises one or more of the following aspects: (1) selectively destroying or inhibiting tumor cell growth in a test subject;
(2) selectively modulating or stimulating the division/growth rate of, for example, brain neural stem cells or neuronal cells;
(3) reducing blood fat; (4) improving arteriosclerosis; (5) preventing the thrombus from blocking the blood vessel; (6) removing toxins from the blood;
(7) modulating autonomic nerves; (8) the immunity of human body is improved by regulating/eliminating free radicals.
The electric field intensity, direction and other properties of the generating device of the space electric field can be adjusted, so that the generating device can selectively destroy or inhibit the growth of tumor cells in a body of a to-be-detected object, and the electric field property of the generating device can be adjusted according to needs to realize other functions.
Experimental protocol
Experiment one: the optimum range of variation in the inter-electrode intensity was found to have inhibitory effects on human melanoma.
Human melanoma has high proliferation and obvious drug resistance, and human melanoma cell lines B16-F10 and A431 (which are cultured in DMEM culture solution containing 10% volume fraction fetal calf serum, 100mg/L mass concentration streptomycin and 100mg/L mass concentration penicillin) at 37 deg.C and 5% volume fraction CO2Culturing under saturated humidity, and carrying out passage for 1 time for 2-3 d.
As described above, the method for counting the number of cancer cells contained in 1 liter of the cancer cell suspension solution: and (3) weighing 20 microliters of the suspension solution with different dilution levels, placing the suspension solution on a cell counting plate, selecting 3-5 visual fields at different positions, and counting the change condition of the number of the cells.
Taking a No. 1-No. 7 cell culture bottle, installing an electrode pair A1 on the No. 1 culture bottle, and setting the electric field intensity to be 1V/cm; the No. 2 culture bottle is provided with an electrode pair A2, and the electric field intensity between the electrodes is 10V/cm; the No. 3 culture bottle is provided with an electrode pair A3, and the electric field intensity between the electrodes is 100V/cm; the No. 4 culture bottle is provided with an electrode pair A4, and the electric field intensity between the electrodes is 1 KV/cm; the No. 5 culture bottle is provided with an electrode pair A5, and the electric field intensity between the electrodes is 10 KV/cm; the No. 6 culture bottle is provided with an electrode pair A6, and the electric field intensity between the electrodes is 120 KV/cm; no. 7 flask was used as a control without access to the electrodes. 2 ml of culture solution was added to each flask, and 1X10 was added thereto5After each cell, the cells were left standing in 5% carbon dioxide; after incubation in an incubator at 37 ℃ for 2-3 hours, the electric field treatment of A1-A7 as described above was applied. The cell culture flasks were removed 24-48 hours after the start of the treatment and the cells were counted. And counting the change of the tumor cells according to the counting result.
The results are shown in tables 1 and 2.
None: the cell number of the treatment group is not different from that of the control group
The inhibition efficiency (number of living cells in the control group-number of living cells in the treatment group)/number of living cells in the control group was the greatest when the number of living cells in the treatment group was zero or the number of living cells in the control group was less than one thousandth of the number, and the inhibition was marked as 100%.
As shown in Table 1, the electric field treatment effect tends to be significantly enhanced with an increase in the electric field intensity. After only 1 treatment for 24hr, the effect of killing human melanoma cell lines appears when the electric field strength is greater than 1 KV/cm. When the electric field power reaches 10KV/cm, the treatment lasts for 24hr, and almost all cells are killed (the effect of killing cells is shown in figure 3).
As shown in Table 2, the electric field treatment effect tends to be significantly enhanced with an increase in the electric field intensity. After 1 time and 48hr treatment, the effect of killing human melanoma cell lines appears when the electric field intensity is more than 1 KV/cm. When the electric field power reaches 3KV/cm, almost all cells are killed after 48hr treatment (the effect of killing cells is shown in figure 4). With the same killing effect, the treatment group required nearly 2-fold higher electric field strength at 24 hr. It is expected that there is a significant correlation between the electric field strength and the efficiency of killing cells.
Experiment two: an optimum range of variation in the inter-electrode strength was found to have an inhibitory effect on human glioblastoma.
The electric field intensity for inhibiting the most strongly of the glioblastoma strains (SNB-19 and A172) is 120kV/cm, the cells are cultured in DMEM or RPMI1640 medium (containing 10% volume fraction of fetal bovine serum and 100mg/L mass concentration of streptomycin and penicillin), and 5% volume fraction of CO2Culturing under saturated humidity, and carrying out passage for 1 time for 2-3 d.
As described above, the method for counting the number of cancer cells contained in 1 liter of the cancer cell suspension solution: diluting the cancer cell suspension solution to different dilution levels, measuring 20 microliters of suspension solution with different dilution levels, placing the suspension solution on a cell counting disc, selecting 3-5 visual fields at different positions, and counting the change condition of the cell number.
Taking a No. 1-No. 7 cell culture bottle, installing an electrode pair A1 on the No. 1 culture bottle, and setting the electric field intensity to be 1V/cm; the No. 2 culture bottle is provided with an electrode pair A2, and the electric field intensity between the electrodes is 10V/cm; the No. 3 culture bottle is provided with an electrode pair A3, and the electric field intensity between the electrodes is 100V/cm; the No. 4 culture bottle is provided with an electrode pair A4, and the electric field intensity between the electrodes is 1 KV/cm; the No. 5 culture bottle is provided with an electrode pair A5, and the electric field intensity between the electrodes is 10 KV/cm; the No. 6 culture bottle is provided with an electrode pair A6, and the electric field intensity between the electrodes is 120 KV/cm; no. 7 flask was used as a control without access to the electrodes. 2 ml of culture solution was added to each flask, and 1X10 was added thereto5After each cell, the cells were left standing in 5% carbon dioxide; after incubation in an incubator at 37 ℃ for 2-3 hours, the electric field treatment of A1-A7 as described above was applied. The cell culture flasks were removed 24 hours and 48 hours after the start of the treatment and counted. And counting the change of the tumor cells according to the counting result.
None: the cell number of the treatment group is not different from that of the control group
The inhibition efficiency (number of living cells in the control group-number of living cells in the treatment group)/number of living cells in the control group was the greatest when the number of living cells in the treatment group was zero or the number of living cells in the control group was less than one thousandth of the number, and the inhibition was marked as 100%.
As shown in Table 3, the electric field treatment effect tends to be significantly enhanced with an increase in the electric field intensity. After only 1 treatment for 24hr, the effect of killing human brain glioma cell lines appears when the electric field strength is more than 1 KV/cm. When the electric field power reaches 10KV/cm, the treatment lasts for 24hr, and almost all cells are killed. The effect of killing cells is shown in FIGS. 5-6.
As shown in Table 4, the electric field treatment effect tends to be significantly enhanced with an increase in the electric field intensity. After 1 time and 48hr treatment, the effect of killing human glioma cell lines appears when the electric field intensity is more than 1 KV/cm. When the electric field power reaches 3KV/cm, almost all cells are killed after 48hr of treatment. With the same killing effect, the treatment group required nearly 2-fold higher electric field strength at 24 hr. It is expected that there is a significant correlation between the electric field strength and the efficiency of killing cells.
In the experiments described in tables 3 and 4, there was a phenomenon in which A72 showed an increase in the number of tumor cells after the first discovery of the treatment in the 1KV/cm (24hr treatment group) and 100V/cm and 1KV/cm (48hr) treatment groups. Further exploration (date not shown) was conducted with ROI (core tube friction region) of 100v/cm to 3 KV/cm. We have found an interesting phenomenon. Electric field sensitive cells like glioma cell A172 show a phenomenon of two distinct differentiation rates of cell growth under different electric field stress states. The discovery of this phenomenon means that electric field sensitive cells, living tissues, organs, soft tissues, and the like will have the following various applications. Such as: selectively destroying or inhibiting tumor cell growth in a test subject; selectively modulating or stimulating the division/growth rate of, for example, brain neural stem cells or neuronal cells; reducing blood fat; improving arteriosclerosis; preventing the thrombus from blocking the blood vessel; removing toxins from the blood; regulating autonomic nerve or regulating/eliminating free radicals, and improving immunity.
Experiment three: imaging observation of tumor cell growth before and after treatment
Mouse melanoma cells were grown on coverslips and cultured in TT-fields for 24 and 48 hours. After treatment, the medium was removed and buffered [10mM 4-morpholinoethanesulfonic acid, 150mM NaCl, 5mM EGTA, 5mM MgCl ]2And 5mM glucose (pH6.1)]The cells were washed, permeabilized and fixed with 0.5% Triton X-100 and 0.25% glutaraldehyde (sigma) 5Minutes, then fixed with 1% glutaraldehyde for 20 minutes and photographed.
Experiment four: establishment of mouse subcutaneous tumor model and electric field treatment experiment
Mice were cultured in cages in the absence of specific pathogens. Taking tumor cells in logarithmic growth phase, digesting with pancreatin with volume fraction of 0.25%, and adding 5 × 10 for each6mL-1The cell number density of (2) was resuspended in PBS and then inoculated into the right forelimb of the mouse. After 3 weeks, subcutaneous solid tumors of 1cm × 1cm in size were formed and randomly divided into 2 groups: control and experimental groups of 12 individuals each. The experimental mice were treated with electric field, and the control mice were not treated with electric field.
Tumor growth inhibition was recorded: taking pictures of nude mice tumors and body mass changes every 1d as the initial 1d on the day of electric field treatment, measuring the maximum transverse diameter a and the maximum longitudinal diameter b of the tumors of the experimental group and the control group by a vernier caliper every 2d, and calculating according to the formula V as ab2The tumor volume V was calculated 2.
HE staining observed inflammatory cell infiltration in tumors after treatment: after 24h of electric field treatment, 4 mice are randomly extracted from an experimental group and a control group respectively to be killed and tumor-taken, after the mice are fixed for 20h at room temperature by using 4% by volume of paraformaldehyde, the mice are dehydrated, embedded and paraffin-sectioned conventionally, 6 specimens are taken, and inflammatory cell infiltration is observed under a light mirror after HE staining.
As shown in fig. 7, the day of initiation of electric field treatment was set to D0, and the body weight and tumor volume were measured after anesthetizing the experimental group every 2 days after initiation of treatment. Tumor volume was calculated according to the elliptical volume calculation formula V ═ major diameter ═ minor diameter/2. The body weight of the first experiment varied almost without significant change from D0 to D24. The body surface of the experimental animal has no obvious signs of scald, depilation and the like. The test is carried out on the preferred 60KV/cm middle electric field intensity interval of the treatment electric field intensity. The growth trend of the tumor volume on the surface of the experimental animal tends to be stable after about one week of treatment. D6-D12 were in the stationary phase, and continued treatment with D12 started the tumor volume to decrease, and by D24, the tumor volume showed a continuous decrease.
The foregoing embodiments are merely illustrative of the principles and utilities of the present invention and are not intended to limit the invention. Any person skilled in the art can modify or change the above-mentioned embodiments without departing from the spirit and scope of the present invention. Accordingly, it is intended that all equivalent modifications or changes which can be made by those skilled in the art without departing from the spirit and technical spirit of the present invention be covered by the claims of the present invention.
Claims (14)
1. A device for generating an electric field in space, characterized in that it comprises at least:
a space electric field contact electrode;
the space electric field outer electrode is used for forming a space electric field with the space electric field contact electrode; the device comprises more than 2 different electrodes, and the positions of the different electrodes are adjustable and are used for adjusting the coverage area of a space electric field.
2. The device for generating a spatial electric field according to claim 1, wherein: further comprising one or more of the following features:
1) the space electric field contact electrode is used for being connected with an object to be detected, so that the object to be detected and the space electric field contact electrode form an equipotential;
2) the space electric field contact electrode is grounded;
3) the generating device further comprises:
the power supply is used for supplying electric energy to the generating device;
the regulating and controlling unit is used for regulating and controlling the performance of the space electric field, and comprises one or more of electric field intensity, electric field direction, electric field pulse frequency and electric field lattice range;
4) the different electrode is a point-shaped probe;
5) the arrangement mode of the different electrodes is selected from lattice arrangement and is 2nLattice, where n is a non-0 natural number.
3. The device for generating a spatial electric field according to claim 2, wherein: further comprising one or more of the following features:
1) in the characteristic 1), the space electric field contact electrode is in conductive contact with an object to be detected through water;
2) in the characteristic 1), the outer electrode of the space electric field is not contacted with an object to be detected;
3) in feature 3), the position of the hetero-electrode and/or the performance of the spatial electric field is confirmed from other diagnostic data; and/or the position, the number and/or the space electric field performance of the different electrodes are automatically tracked and adjusted after being diagnosed according to the electric field coupling current;
4) in the characteristic 3), the power supply is a high-voltage output power supply;
5) in the characteristic 3), the voltage of the power supply is adjustable to 0.001kv-120kv, the current output is adjustable to 0.001ma-10000ma, and the working distance of the electric field is adjustable to 0.1cm-100 cm.
4. The device for generating a spatial electric field according to claim 1, wherein: the method for confirming the electric field intensity of the space electric field comprises the following steps:
1) culturing tumor cells under electric fields with different electric field intensities, and counting the lethality rate of the tumor cells, wherein the tumor cells are the same as the tumor types suffered by the object to be detected;
2) and selecting the electric field intensity range of the group with the highest tumor cell lethality as the electric field intensity range of the space electric field.
5. A method for generating a space electric field, comprising at least the following steps:
1) providing a space electric field contact electrode, and enabling the space electric field contact electrode to contact a living organism;
2) providing a space electric field outer electrode, wherein the space electric field outer electrode comprises more than 2 different electrodes, and the position of each different electrode is adjustable and is used for adjusting the coverage area of the space electric field;
3) and switching on the space electric field contact electrode and the space electric field outer electrode to generate a space electric field.
6. The method according to claim 5, further comprising adjusting and controlling the properties of the space electric field, including one or more of electric field intensity, electric field direction, electric field pulse frequency, and electric field lattice range.
7. The method of generating a spatial electric field according to claim 5, further comprising one or more of the following features:
1) the space electric field contact electrode is grounded;
2) the different electrode is a point-shaped probe;
3) the arrangement mode of the different electrodes is selected from lattice arrangement and is 2nA lattice, wherein n is a non-0 natural number;
4) the space electric field contact electrode is in conductive contact with the living organism through water;
5) the outer electrode of the space electric field is not contacted with a living organism;
6) the voltage of the power supply is adjustable to be 0.001kv-120kv, the current output is adjustable to be 0.001ma-10000ma, and the working distance of the electric field is adjustable to be 0.1cm-100 cm.
8. The method for generating a space electric field according to claim 6, wherein the method for confirming the electric field intensity of the space electric field comprises the steps of:
1) culturing tumor cells under electric fields with different electric field intensities, and counting the lethality rate of the tumor cells, wherein the tumor cells are the same as the tumor types suffered by the object to be detected;
2) and selecting the electric field intensity range of the group with the highest tumor cell lethality as the electric field intensity range of the space electric field.
9. Method for using a device for generating an electric field in space according to any one of claims 1 to 4, characterized in that it comprises at least the following steps:
1) connecting the space electric field contact electrodes of the object to be detected to enable the object to be detected and the space electric field contact electrodes to form an equipotential;
2) and adjusting the position of each different electrode to adjust the coverage area of the space electric field.
10. Use of a device for generating an electric field in space according to claim 9, characterized in that it further comprises one or more of the following features:
1) the space electric field contact electrode is grounded;
2) the different electrode is a point-shaped probe;
3) the arrangement mode of the different electrodes is selected from lattice arrangement and is 2nA lattice, wherein n is a non-0 natural number;
4) the space electric field contact electrode is in conductive contact with an object to be detected through water;
5) the outer electrode of the space electric field is not contacted with an object to be detected;
6) the voltage of the power supply is adjustable to be 0.001kv-120kv, the current output is adjustable to be 0.001ma-10000m, and the working distance of the electric field is adjustable to be 0.1cm-100 cm;
7) the use method further comprises the following steps:
and adjusting and controlling the performance of the space electric field, wherein the performance comprises one or more of electric field intensity, electric field direction, electric field pulse frequency and electric field lattice range.
11. The method for using a device for generating an electric field in space according to claim 10, wherein in feature 7), the position of the different electrode and/or the performance of the electric field in space is confirmed based on other diagnostic data; and/or the position, the number and/or the space electric field performance of the different electrodes are automatically tracked and adjusted after being diagnosed according to the electric field coupling current.
12. The method for using a device for generating an electric field in space according to claim 10, wherein in feature 7), the method for confirming the electric field strength of the electric field in space comprises the steps of:
1) culturing tumor cells under electric fields with different electric field intensities, and counting the lethality rate of the tumor cells, wherein the tumor cells are the same as the tumor types suffered by the object to be detected;
2) and selecting the electric field intensity range of the group with the highest tumor cell lethality as the electric field intensity range of the space electric field.
13. A method for selectively destroying or inhibiting tumor cell growth in a subject by exposing the subject to the device for generating a spatial electric field according to any one of claims 1-4.
14. Use of a device for generating an electric space field according to any of claims 1 to 4 or a method for generating an electric space field according to any of claims 5 to 8, comprising one or more of:
(1) selectively destroying or inhibiting tumor cell growth in a test subject;
(2) selectively modulating or stimulating the division/growth rate of, for example, brain neural stem cells or neuronal cells;
(3) reducing blood fat; (4) improving arteriosclerosis; (5) preventing the thrombus from blocking the blood vessel; (6) removing toxins from the blood;
(7) modulating autonomic nerves; (8) the immunity of human body is improved by regulating/eliminating free radicals.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2019102923964 | 2019-04-12 | ||
| CN201910292396 | 2019-04-12 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN111803792A true CN111803792A (en) | 2020-10-23 |
Family
ID=72750959
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010285056.1A Pending CN111803792A (en) | 2019-04-12 | 2020-04-13 | Generating device of space electric field |
Country Status (2)
| Country | Link |
|---|---|
| CN (1) | CN111803792A (en) |
| WO (1) | WO2020207488A1 (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113082519A (en) * | 2021-04-30 | 2021-07-09 | 杭州维那泰克医疗科技有限责任公司 | Device for destroying or inhibiting division of diseased cells and control method thereof |
| WO2024093734A1 (en) * | 2022-11-03 | 2024-05-10 | 赛福凯尔(绍兴)医疗科技有限公司 | Electric field energy-focused emitting device and method |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1359734A (en) * | 2000-12-18 | 2002-07-24 | 株式会社白寿生科学研究所 | Potential therapy device and method for controlling proper physiotherapeutic dose in human dody position |
| US20060149341A1 (en) * | 2004-12-07 | 2006-07-06 | Yoram Palti | Electrodes for applying an electric field in-vivo over an extended period of time |
| US20060167499A1 (en) * | 2000-02-17 | 2006-07-27 | Standen Ltd | Treating a tumor or the like with electric fields at different orientations |
| US20110137381A1 (en) * | 2006-07-05 | 2011-06-09 | Harry Lee | Treatment of neurological disorders via electrical stimulation, and methods related thereto |
| US20170281934A1 (en) * | 2016-04-04 | 2017-10-05 | Novocure Limited | Reducing Motility of Cancer Cells Using Tumor Treating Fields (TTFields) |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3885573A (en) * | 1973-03-20 | 1975-05-27 | Hakuju Inst For Health Science | Therapeutical apparatus applying superposed output of DC and AC voltages |
| US4094322A (en) * | 1976-06-18 | 1978-06-13 | Hakuju Institute For Health Science Co., Ltd. | Therapeutical apparatus using electric field |
| JP2006167476A (en) * | 2004-12-17 | 2006-06-29 | Hakuju Inst For Health Science Co Ltd | Methods for treating disease with electric field |
| CN208405772U (en) * | 2017-10-10 | 2019-01-22 | 无锡健寿医疗科技有限公司 | A kind of field energy health instrument for simulating the earth's electric field |
-
2020
- 2020-04-13 WO PCT/CN2020/084382 patent/WO2020207488A1/en active Application Filing
- 2020-04-13 CN CN202010285056.1A patent/CN111803792A/en active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060167499A1 (en) * | 2000-02-17 | 2006-07-27 | Standen Ltd | Treating a tumor or the like with electric fields at different orientations |
| CN1359734A (en) * | 2000-12-18 | 2002-07-24 | 株式会社白寿生科学研究所 | Potential therapy device and method for controlling proper physiotherapeutic dose in human dody position |
| US20060149341A1 (en) * | 2004-12-07 | 2006-07-06 | Yoram Palti | Electrodes for applying an electric field in-vivo over an extended period of time |
| US20110137381A1 (en) * | 2006-07-05 | 2011-06-09 | Harry Lee | Treatment of neurological disorders via electrical stimulation, and methods related thereto |
| US20170281934A1 (en) * | 2016-04-04 | 2017-10-05 | Novocure Limited | Reducing Motility of Cancer Cells Using Tumor Treating Fields (TTFields) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113082519A (en) * | 2021-04-30 | 2021-07-09 | 杭州维那泰克医疗科技有限责任公司 | Device for destroying or inhibiting division of diseased cells and control method thereof |
| WO2024093734A1 (en) * | 2022-11-03 | 2024-05-10 | 赛福凯尔(绍兴)医疗科技有限公司 | Electric field energy-focused emitting device and method |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2020207488A1 (en) | 2020-10-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11701161B2 (en) | Optimizing treatment using TTFields by changing the frequency during the course of long term tumor treatment | |
| US10994133B2 (en) | Methods for enhancing and modulating reversible and irreversible electroporation lesions by manipulating pulse waveforms | |
| US9655669B2 (en) | Optimizing treatment using TTFields by changing the frequency during the course of long term tumor treatment | |
| EP2183024B1 (en) | Treating parasites with electric fields | |
| US7599746B2 (en) | Apparatus and method for preventing the spread of cancerous metastases and for elimination of metastases | |
| Kincaid et al. | Inhibition of bacterial growth in vitro following stimulation with high voltage, monophasic, pulsed current | |
| Hart et al. | The application of electric fields in biology and medicine | |
| Graves et al. | Electrically mediated neuronal guidance with applied alternating current electric fields | |
| CN112807074A (en) | Electroporation system | |
| EP3668430B1 (en) | Targeted remote electrostimulation by interference of bipolar nanosecond pulses | |
| Dermol-Černe et al. | Plasma membrane depolarization and permeabilization due to electric pulses in cell lines of different excitability | |
| CN111803792A (en) | Generating device of space electric field | |
| KR102556144B1 (en) | Megahertz compression of nanosecond pulse bursts | |
| US20110230939A1 (en) | System for diagnosing and treatment of diabetic symptoms | |
| CN207477801U (en) | A kind of device using amplitude modulation electric field treatment tumour | |
| CN104759039A (en) | Transcranial Hall effect brain regulating and controlling device and method | |
| CN111172151B (en) | Method for regulating and controlling immune response of organism by regulating presentation of skin DCs/LCs to T cells through electric signals and application of method | |
| Dumitru et al. | Far‐field potentials in circular volumes: The effect of different volume sizes and intercompartmental openings | |
| CN111821564A (en) | Generating device of nervous system disease treatment electric field | |
| Mir | Electrochemotherapy and Electric Pulses | |
| Gomez | Impedance Measurements as a Means to Improve the Biological Response of Gene Electrotransfer | |
| Pradhan et al. | A hierarchical neural stimulation model for pain relief by variation of coil design parameters | |
| Fajardo Gomez | Impedance Measurements as a Means to Improve the Biological Response of Gene Electrotransfer | |
| Zhu et al. | Effects of direct electric pulse on tissues of tumors in mice | |
| KR20170001073A (en) | A mechanical device that simultaneously outputs multiple stimulation and monopole electrodes |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |